How to Handle Polypharmacy in Heart Failure. A Clinical Consensus Statement of the Heart Failure Association of the ESC
Davide Stolfo(Azienda Ospedaliero Universitaria Ospedali Riuniti), Gianluigi Savarese(Karolinska Institutet), Basil S. Lewis(Carmel Medical Center), Antoni Bayés‐Genís(Universitat Autònoma de Barcelona), Pardeep S. Jhund(Copenhagen University Hospital), Maurizio Volterrani, Sophie Van Linthout(Franklin University), Antonio Cannatà(University of Trieste), Massimo Iacoviello(University of Foggia), Carlo G. Tocchetti(Federico II University Hospital), Ovidiu Chioncel, Frieder Braunschweig(Karolinska University Hospital), Giuseppe Rosano(Vita-Salute San Raffaele University), Petar Seferović, Alexandre Mebazaa, Arsen Ristić, Sven Waßmann(Universitätsklinikum des Saarlandes), Hadi Skouri(American University of Beirut Medical Center), Massimo Piepoli, Cristiana Vitale(St George's, University of London), Kalliopi Keramida(National and Kapodistrian University of Athens), Seif El Hadidi(University of Hertfordshire), Robin Ray(St George’s University Hospitals NHS Foundation Trust), Brenda Moura(Universidade do Porto), Maggie Simpson(Queen Elizabeth University Hospital), Marco Metra(Surgical Specialties (Canada)), Markus S. Anker(Berlin-Brandenburger Centrum für Regenerative Therapien)
Cited by 36
Related Papers
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2009|11.2k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
2016 European Guidelines on cardiovascular disease prevention in clinical practice
|European Heart Journal|2016|6.5k